Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Inhaled triple therapy in chronic obstructive pulmonary disease

In the TRIBUTE study,1 Alberto Papi and colleagues (March 17, p 1076) reported a small but significant reduction of the exacerbation rate with the addition of an inhaled corticosteroid to dual long-acting bronchodilation in patients with chronic obstructive pulmonary disease and severe or very severe airway obstruction with at least one exacerbation in the previous year. Data derived from the ISOLDE study2 showed that abruptly stopping treatment with inhaled corticosteroid was associated with an increased risk of exacerbation in about 25% of patients, with a median delay of 20 days.